ライフサイエンスコーパス: pharmacokinetics

1 a library of nanoparticles on their in vivo pharmacokinetics.

2 e (18)F-FLT biodistribution and to determine pharmacokinetics.

3 concentrations, which matched their expected pharmacokinetics.

4 oblasts, thereby impairing drug activity and pharmacokinetics.

5 regular intervals to determine (68)Ga-OPS202 pharmacokinetics.

6 myricetin might improve its pharmacology and pharmacokinetics.

7 hology and distribution kinetics with plasma pharmacokinetics.

8 intramuscular administration and undesirable pharmacokinetics.

9 edicinal chemists to achieve acceptable oral pharmacokinetics.

10 ance of cancer cells and in determining drug pharmacokinetics.

11 human microdose study to determine clinical pharmacokinetics.

12 of nNOS inhibitors is often hindered by poor pharmacokinetics.

13 sue, without changing (11)C-erlotinib plasma pharmacokinetics.

14 omic modifications rather than by short-term pharmacokinetics.

15 oups differ substantially in tolerability or pharmacokinetics.

16 there is large inter-patient variability in pharmacokinetics.

17 vivo markers of efficacy, side effects, and pharmacokinetics.

18 aximum tolerated dose and to evaluate plasma pharmacokinetics.

19 nd suboptimal serum stability, efficacy, and pharmacokinetics.

20 ated side effects, and also may improve drug pharmacokinetics.

21 lture and enables estimation of the cellular pharmacokinetics.

22 apy (ART) coadministration on levonorgestrel pharmacokinetics.

23 similar molecular weight and albumin driven pharmacokinetics.

24 ibution of GSK1265744 LAP and its associated pharmacokinetics.

25 proportional, with no effect on capecitabine pharmacokinetics.

26 points were DSM265 safety, tolerability, and pharmacokinetics.

27 olecular components controlling asparaginase pharmacokinetics.

28 ke mechanisms, biodistribution patterns, and pharmacokinetics.

29 there is large inter-patient variability in pharmacokinetics.

30 tant window into the study of physiology and pharmacokinetics.

31 atively characterize via 6 shape features, 3 pharmacokinetics, 4 enhancement kinetics, 4 intensity ki

32 Drug delivery can affect drug pharmacokinetics, absorption, distribution, metabolism,

33 on, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK) properties of new chemical en

34 We compare the pharmacokinetics and anti-Wolbachia efficacy in a murine

35 argeted to red blood cells (RBCs) to improve pharmacokinetics and antithrombotic effects without incr

36 tabolic processing of STO-609, its toxicity, pharmacokinetics and bioavailability in a variety of mou

37 e data will augment our understanding of the pharmacokinetics and biodistribution of radiolabeled pem

38 g strategy to simultaneously investigate the pharmacokinetics and biodistribution of the polymer carr

39 While dose dependencies in pharmacokinetics and clearance are often observed in cli

40 Here we report that the pharmacokinetics and clearance of renal clearable gold n

41 f gel application relative to sex may impact pharmacokinetics and contribute to outcomes.

42 iotics across cell membranes, affecting drug pharmacokinetics and contributing to the development of

43 n in rats was assessed by determining plasma pharmacokinetics and deposition in selected tissues.

44 To test this hypothesis, we compared their pharmacokinetics and distribution in peripheral nerve ti

45 odistribution studies were used to determine pharmacokinetics and dosimetry.

46 We assessed the pharmacokinetics and effects on cardiac function and str

47 BPTES nanoparticles demonstrated improved pharmacokinetics and efficacy compared with unencapsulat

48 to long-acting rilpivirine for assessment of pharmacokinetics and ex-vivo biopsy challenge with HIV-1

49 ovascular diseases are limited by short-term pharmacokinetics and extra-cardiac adverse effects.

50 nted in 99 coronary arteries of 37 swine for pharmacokinetics and healing evaluation at various time

51 s in vitro and showed significantly improved pharmacokinetics and hepatocyte transduction in vivo.

52 intravenous (IV) infusion and to assess the pharmacokinetics and in vitro immunologic activity of th

53 harmacokinetics, spatial and temporal tissue pharmacokinetics and in vitro pharmacodynamics of these

54 analyte, an insightful understanding of the pharmacokinetics and in vivo biotransformation of dulagl

55 n IgA antibody can significantly improve its pharmacokinetics and its therapeutic efficacy to inhibit

56 The pharmacokinetics and metabolic stability of the probes w

57 This led to compounds with good pharmacokinetics and oral activity in a P. berghei mouse

58 Pharmacokinetics and PET imaging were studied in nude mi

59 formation and function, FQ plasma and tissue pharmacokinetics and pharmacodynamics and is based on ex

60 this study, the authors sought to study the pharmacokinetics and pharmacodynamics for ticagrelor 60

61 The pharmacokinetics and pharmacodynamics of lumefantrine, a

62 genes that express proteins involved in the pharmacokinetics and pharmacodynamics of rasagiline, and

63 Secondary outcomes were the pharmacokinetics and pharmacodynamics of ricolinostat in

64 stematic approach was taken by analysing the pharmacokinetics and pharmacodynamics of single doses of

65 The pharmacokinetics and pharmacodynamics of ticagrelor 60 m

66 s that should be considered, including viral pharmacokinetics and pharmacodynamics, potential toxic e

67 lerance, multiple comorbidities, and altered pharmacokinetics and pharmacodynamics.

68 ein therapeutics and for understanding their pharmacokinetics and pharmacodynamics.

69 During therapy, pharmacokinetics and radiation dosimetry were evaluated.

70 Primary outcomes were pharmacokinetics and safety, analysed in all patients wh

71 man subjects evaluated safety, tolerability, pharmacokinetics and sleep-promoting effects of MK-1064,

72 The compounds display favorable in vivo pharmacokinetics and stability.

73 cholesteryl design-based strategy for tuning pharmacokinetics and systemic gene silencing.

74 a carrier for targeted delivery can improve pharmacokinetics and the therapeutic index.

75 conjugates exhibited significantly improved pharmacokinetics and therapeutic effects over the native

76 Here, we evaluate the long-term pharmacokinetics and therapeutic efficacy of polycaprola

77 rent preclinical study is to investigate the pharmacokinetics and tolerability of NSC23925b, a novel

78 Pharmacokinetics and toxicity studies in rats confirmed

79 nal antibodies, Alexa750 labeling can change pharmacokinetics and trigger liver uptake.

80 this study, we used PET imaging to study the pharmacokinetics and tumor delivery of a panel of anti-E

81 he in vivo stability of Lx and its effect on pharmacokinetics and tumor targeting of an ADC, Lx-DFO w

82 amolecular platforms that improved porphyrin pharmacokinetics and tumour-homing.

83 exists in how patients metabolize the drug (pharmacokinetics) and the magnitude and duration of resp

84 aim of this study was to assess the safety, pharmacokinetics, and activity of venetoclax in combinat

85 eek cycles and were assessed for toxicities, pharmacokinetics, and antitumor activity.

86 y was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of a single dose

87 PR scaffolds exhibit absorption, pharmacokinetics, and biodistribution patterns that are

88 ts toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity.

89 imaging to evaluate the safety, feasibility, pharmacokinetics, and dosimetry of (18)F-MFBG in neuroen

90 n study of oral leniolisib to assess safety, pharmacokinetics, and effects on lymphoproliferation and

91 ere further evaluated for in vitro toxicity, pharmacokinetics, and efficacy in a mouse peritonitis mo

92 We aimed to assess the safety, tolerability, pharmacokinetics, and efficacy of AZD3759 in patients wi

93 We aimed to assess safety, pharmacokinetics, and efficacy of this single-tablet, fi

94 with NHL was conducted to determine safety, pharmacokinetics, and efficacy of venetoclax, a selectiv

95 cal proof of concept, specific tumor uptake, pharmacokinetics, and feasibility for intraoperative flu

96 e dose (MTCD) and evaluate safety, activity, pharmacokinetics, and immunogenicity of moxetumomab pasu

97 End points were safety, response, pharmacokinetics, and immunogenicity.

98 te the role of chemical-specific properties, pharmacokinetics, and internal exposure dynamics in the

99 Si nanoparticle colloidal stability, in vivo pharmacokinetics, and intracellular bioavailability thro

100 However, little is known about its pharmacokinetics, and mechanisms of therapy resistance a

101 ine (Gd-DTPA) and to evaluate the excretion, pharmacokinetics, and metabolism of Mn-PyC3A.

102 rate, progression-free and overall survival, pharmacokinetics, and modulation of phosphorylated cycli

103 ssment; secondary endpoints included safety, pharmacokinetics, and overall response.

104 relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.

105 an study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of avoralstat.

106 compare the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of GP2013 plus cy

107 We aimed to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in c

108 conducted to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant hu

109 e compartment model can describe doxorubicin pharmacokinetics, and pharmacokinetic parameters vary si

110 This phase 1 study evaluated the safety, pharmacokinetics, and preliminary activity of vadastuxim

111 PET/CT-based biodistribution, pharmacokinetics, and radiation dosimetry were performed

112 e design, discovery, pharmacologic activity, pharmacokinetics, and safety of a CD3 T cell-dependent b

113 of 71 (79) displayed more optimal efficacy, pharmacokinetics, and safety, leading to its selection a

114 Materials and Methods Biodistribution, pharmacokinetics, and stability of CM-101 in rats were m

115 ort expansions to provide additional safety, pharmacokinetics, and target occupancy data.

116 improve potency, physicochemical properties, pharmacokinetics, and the safety profile of GPR119 agoni

117 fort is required to improve the selectivity, pharmacokinetics, and toxicity profiles of HDACIs to ach

118 illars of drug development-pharmacodynamics, pharmacokinetics, and toxicity studies-which, in additio

119 mpact by surface coating on biodistribution, pharmacokinetics, and tumor retention.

120 rostate-specific antigen, and pain response; pharmacokinetics; and health-related quality of life.

121 t at molecular level; iii) effect related to pharmacokinetics; and iv) DDIs without known ADRs.

122 Secondary outcomes were pharmacokinetics, annual bleeding rate (ABR), spontaneou

123 al studies investigating the drug safety and pharmacokinetics are ongoing.

124 al challenges centered on chemistry, such as pharmacokinetics, are reduced.

125 y, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets i

126 We aimed to determine apixaban pharmacokinetics at steady state in patients on hemodial

127 This compound showed the most favorable pharmacokinetics because of its high polarity (log D = -

128 Poor circulation stability causes loss of pharmacokinetics benefits of nanoparticles.

129 -positive EGA; here, we evaluate the safety, pharmacokinetics, biodistribution, and dosimetry (89)Zr-

130 In this study, we evaluated the pharmacokinetics, biodistribution, and dosimetry of pemb

131 ts, and blood draws were performed to assess pharmacokinetics, biodistribution, and dosimetry.

132 od drawing were performed over 8 d to assess pharmacokinetics, biodistribution, and dosimetry.

133 ness was marginally associated with fentanyl pharmacokinetics but did not improve the model fit after

134 There was no interference to gemcitabine pharmacokinetics by IVC administration.

135 dies of any size or design that compared the pharmacokinetics, clinical efficacy, adverse events, or

136 Preclinical pharmacokinetics conducted in several species were predi

137 higher stability and potency with prolonged pharmacokinetics could be compatible with very infrequen

138 eutic doses, determined from serum and urine pharmacokinetics, did not affect urine output, osmolalit

139 th excellent potency and drug metabolism and pharmacokinetics (DMPK) properties was initiated based u

140 MV) met the efficacy and drug metabolism and pharmacokinetics (DMPK) requirements for a malaria drug

141 ecures a long serum half-life and favourable pharmacokinetics due to its pH-dependent interaction wit

142 A pharmacokinetics evaluation of the therapeutic Ab reveal

143 A from thermal paper receipts occurs but BPA pharmacokinetics following dermal exposure is not unders

144 based tracer (99m)Tc-RYM1 displays favorable pharmacokinetics for early vascular imaging and enables

145 er with excellent tumor uptake and favorable pharmacokinetics for imaging and therapy of GRPR-express

146 Population pharmacokinetics for lumefantrine used a 2-compartment o

147 compounds, including D1 agonists with better pharmacokinetics, functionally selective D1 ligands, and

148 The Phase-1 evaluation of safety and pharmacokinetics has been completed, allowing for the in

149 peracillin-tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese critic

150 hat [(18)F]BF4(-) was superior due to better pharmacokinetics, i.e. faster tumor uptake and faster an

151 Safety, efficacy, pharmacokinetics, immunogenicity, and accelerated daratu

152 transferase (AT) inhibitor, shows comparable pharmacokinetics, improved safety and tolerability, and

153 drimer size on brain uptake and explored the pharmacokinetics in a clinically-relevant canine model o

154 We explored the pharmacodynamics and pharmacokinetics in a rabbit model.

155 et the sensitivity requirement to assess the pharmacokinetics in a toxicology study.

156 y-phase trials that assess dose, safety, and pharmacokinetics in a variety of tumor types and later p

157 highly potent, selective, and achieved good pharmacokinetics in dogs with oral dosing.

158 The current study characterizes (18)F-T807 pharmacokinetics in human subjects using dynamic PET ima

159 ule radiotracer and investigated its in vivo pharmacokinetics in mice and pig.

160 subset of the inhibitors as well as in vivo pharmacokinetics in mice for a candidate with promising

161 Pharmacokinetics in mice showed >90% oral bioavailabilit

162 Pharmacokinetics in mice suggested the Cmax to be 12.0 +

163 Modeling of cocaine pharmacokinetics in NAc showed that increased 5-HT6 rece

164 excellent microsomal stability and good oral pharmacokinetics in rats and mice.

165 the identification of 7 which had good oral pharmacokinetics in rats and showed efficacy in a rat ch

166 containing the LALA-PG variant have typical pharmacokinetics in rodents and retain thermostability,

167 ivity over other human NaV isoforms and good pharmacokinetics in rodents.

168 rats and a rhesus monkey to evaluate tracer pharmacokinetics in the brain.

169 s spectrometry (ICP-MS) to examine cisplatin pharmacokinetics in the cochleae of mice and humans.

170 ding affinity for amyloid-beta and desirable pharmacokinetics in the preclinical studies.

171 o two parts: part 1 assessing equivalence of pharmacokinetics (in the pharmacokinetics subset), and p

172 guided by high-resolution, patient-specific pharmacokinetics (including feedback-controlled drug del

173 ns for the mechanism of action, taking Doxil pharmacokinetics into account.

174 Tacrolimus pharmacokinetics is similar with TacHexal and Prograf ea

175 ding SAR, in vitro/in vivo pharmacology, and pharmacokinetics, is reported herein.

176 erivatives while exhibiting greatly improved pharmacokinetics, low projected cost of goods, prophylac

177 e of the scaffold's small size (14 kDa), its pharmacokinetics may be suitable for labeling with the s

178 ssion of therapeutic targets, measuring drug pharmacokinetics, measuring therapy pharmacodynamics, an

179 re measures were determined with a validated pharmacokinetics model.

180 Repetitive sampling for linezolid pharmacokinetics, Mtb intracellular burden, viable monoc

181 EGylation have been developed to improve its pharmacokinetics, none of them have been able to outperf

182 This review outlines the biology and pharmacokinetics of (18)F-FES, highlights the current ex

183 and rats showed similar biodistribution and pharmacokinetics of (89)Zr-Df-pembrolizumab.

184 The pharmacokinetics of (89)Zr-DFO-AC-10 was studied in BALB

185 The pharmacokinetics of (99m)Tc-PSMA-I&S in humans were inve

186 The pharmacokinetics of 6 following a single oral dose indic

187 valuate the biodistribution, metabolism, and pharmacokinetics of a new type I collagen-targeted magne

188 lacebo-controlled phase II evaluation of the pharmacokinetics of ABZ (15 mg/k/d, for 10 days) and PZQ

189 idine dehydrogenase (DPYD) and its effect on pharmacokinetics of and response to 5-fluorouracil (5-FU

190 ion study assessed the safety, efficacy, and pharmacokinetics of anti-CD38 monoclonal antibody isatux

191 Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-tazoba

192 es provide precision tools for analyzing the pharmacokinetics of antibodies in an immune response and

193 We aimed to establish the safety and pharmacokinetics of avelumab in patients with solid tumo

194 harmacokinetic profile with no effect on the pharmacokinetics of capecitabine.

195 To compare the pharmacokinetics of dermal and dietary BPA exposure, six

196 application of the model for optimizing the pharmacokinetics of drug carriers who's circulatory half

197 e investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested its antimalarial

198 cterium tuberculosis, by mimicking pediatric pharmacokinetics of each antibiotic.

199 Overall, the pharmacokinetics of FR104 after a single and double infu

200 endpoints were the safety, tolerability, and pharmacokinetics of gilteritinib.

201 imed to assess the safety, tolerability, and pharmacokinetics of long-acting cabotegravir injections

202 e the neonatal FcR (FcRn) is involved in the pharmacokinetics of mAbs, the interaction of different I

203 it plays important roles in determining the pharmacokinetics of many drugs.

204 Sensitive determination of the pharmacokinetics of PEGylated molecules can accelerate t

205 In a porcine model, pharmacokinetics of PGZ from fat depots transplanted per

206 We aimed to compare pharmacokinetics of piperacillin in severely obese and n

207 Sensitive quantification of the pharmacokinetics of poly(ethylene glycol) (PEG) and PEGy

208 3 study assessing the safety, efficacy, and pharmacokinetics of recombinant factor IX Fc fusion prot

209 The pharmacokinetics of ricolinostat and lenalidomide were n

210 We aimed to assess the efficacy, safety, and pharmacokinetics of rilotumumab combined with epirubicin

211 We studied the pharmacokinetics of rilpivirine 25 mg once daily in HIV-

212 ilot study to test the efficacy, safety, and pharmacokinetics of single-dose DEC, IVM, and ALB in Wuc

213 The pharmacokinetics of sofosbuvir and its metabolite GS-331

214 Obesity alters the pharmacokinetics of some anticoagulant drugs, and IBD pa

215 Reliable methods to define dose and pharmacokinetics of T cell therapies need to be develope

216 However, the pharmacokinetics of the Alexa750-labeled antibody format

217 assessment of the targeting specificity and pharmacokinetics of the antibody-based PET radiotracers

218 has distinct advantages: it can improve the pharmacokinetics of the drug, enhance efficacy, and redu

219 encouraging, but studies are limited by the pharmacokinetics of the drug.

220 The pharmacokinetics of the naltrexone microspheres were inv

221 indicating that the size could affect ocular pharmacokinetics of the nanoparticles.

222 g approach that maintains the native in vivo pharmacokinetics of the nanoparticles.

223 In vivo tumor targeting and pharmacokinetics of the radiotracers were also evaluated

224 The pharmacokinetics of the Tacrolimus Hexal (TacHexal) form

225 and (3) evaluating safety, tolerability and pharmacokinetics of tuberculosis drugs already in use du

226 rum markers of BA synthesis and steady-state pharmacokinetics of ursodeoxycholic acid (UDCA).

227 Pharmacokinetics of ziconotide in CSF following intrathe

228 t model was applied to estimate the cellular pharmacokinetics on CIMR data.

229 In addition to an altered pharmacokinetics (p < 0.01), a reduced pharmacodynamics

230 tudy evaluated maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and s

231 se II dose (RP2D), and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activi

232 Secondary objectives were to evaluate the pharmacokinetics, pharmacodynamics, and clinical antitum

233 Purpose This trial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of seli

234 human study were to characterize the safety, pharmacokinetics, pharmacodynamics, and efficacy, and to

235 End points were incidence of adverse events, pharmacokinetics, pharmacodynamics, and overall response

236 first-in-human study to evaluate the safety, pharmacokinetics, pharmacodynamics, and potency of i.v.

237 This study evaluated the pharmacokinetics, pharmacodynamics, tolerability, safety

238 Here we use pharmacokinetics/pharmacodynamics (PK/PD) analysis to ra

239 rinary output were used to assess furosemide pharmacokinetics/pharmacodynamics parameters.

240 olving gram-positive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the

241 chanism of synergy and optimizing antibiotic pharmacokinetics/pharmacodynamics.

242 aily titrated to 50 mg twice daily guided by pharmacokinetics (pharmacokinetic-titration group), or p

243 patient setting with assessments for safety, pharmacokinetics (PK) and efficacy.

244 f oral OA in patients with ET and assess the pharmacokinetics (PK) and pharmacodynamics (PD) profile

245 r organ-specific processing: terfenadine for pharmacokinetics (PK) and toxicity; trimethylamine (TMA)

246 The pharmacokinetics (PK) studies of immunosuppressive drugs

247 The cellular uptake mechanisms, pharmacokinetics (PK), administration routes and major c

248 rmined on the basis of safety, tolerability, pharmacokinetics (PK), and by mRNA expression of the p53

249 proliferation assays and in vivo using mouse pharmacokinetics (PK).

250 sh correlations between drug concentrations (pharmacokinetics [PK]) and protective efficacy (pharmaco

251 First, we examined the pharmacokinetics (PKs) of methylone and its metabolites

252 We assessed the pharmacodynamics, pharmacokinetics, preliminary efficacy, and safety of BP

253 Further improvement of potency and pharmacokinetics produced in vivo proof-of-concept tool

254 The in vivo pharmacokinetics profile of one of the inhibitors will b

255 ticular, exhibited optimal in vitro ADME and pharmacokinetics properties and dose-dependently counter

256 Compound 27g possessed significantly improve pharmacokinetics relative to that of 4.

257 on-targeted aerosol method produced nicotine pharmacokinetics resembling cigarette smoking in humans.

258 Analyses of SNA biodistribution and pharmacokinetics revealed rapid intratumoral uptake and

259 rome P450 inhibitory activity with excellent pharmacokinetics, safety, and efficacy in rodent models

260 In this study, we aimed to assess the pharmacokinetics, safety, and efficacy of this regimen i

261 ct of simtuzumab on histology or selonsertib pharmacokinetics, selonsertib groups with and without si

262 In vivo dermal pharmacokinetics showed that delivery of just 350mug of

263 The pharmacokinetics shows that both intravenous and subcuta

264 f MET kinase activity, desirable preclinical pharmacokinetics, significant inhibition of MET phosphor

265 any previously described single bnAb, showed pharmacokinetics similar to those of human bnAbs, and co

266 GranSim reproduces in vivo plasma pharmacokinetics, spatial and temporal tissue pharmacoki

267 Biodistribution, pharmacokinetics, SPECT/CT, and dosimetry studies were p

268 In vivo pharmacokinetics studies of 7ii showed high liver distri

269 ated by in vivo imaging technique and ocular pharmacokinetics studies revealing that the clearance of

270 ike molecule and has a half-life of 1 h in a pharmacokinetics study and a reasonable oral availabilit

271 in a rat model show no adverse events, and a pharmacokinetics study documents a peak plasma concentra

272 n all randomised patients (patients from the pharmacokinetics subset plus additional patients enrolle

273 sing equivalence of pharmacokinetics (in the pharmacokinetics subset), and part 2 assessing efficacy

274 Results of ivacaftor pharmacokinetics suggested that exposure was similar to

275 Based on pharmacokinetics, target occupancy, and immunological an

276 Due to unknown pharmacokinetics, the use of Pgp inhibitors to overcome

277 nal and hepatobiliary excretion with similar pharmacokinetics to Gd-DTPA (area under the curve betwee

278 on, South Korea) has equivalent efficacy and pharmacokinetics to rituximab.

279 se hepatic NAD(+) with distinct and superior pharmacokinetics to those of nicotinic acid and nicotina

280 We discuss the pharmacodynamics, pharmacokinetics, toxic effects, and clinical response r

281 results in marked interpatient variation in pharmacokinetics, toxic effects, and efficacy.

282 We employed an integrated strategy combining pharmacokinetics, toxicology, metabonomics, genomics, an

283 for imaging studies or for assessing plasma pharmacokinetics using equipment that has a highly sensi

284 inflammation and organ failure on midazolam pharmacokinetics was developed using NONMEM 7.3.

285 r influence on infliximab (G1m17,1 allotype) pharmacokinetics was investigated in a group of spondylo

286 Equivalence of pharmacokinetics was shown if the 90% CIs for the geomet

287 In an attempt to improve its poor oral pharmacokinetics, we synthesized a series of prodrugs by

288 Pharmacokinetics were assessed in a subset of the safety

289 Safety measures and pharmacokinetics were assessed, and pharmacodynamics wer

290 Piperaquine pharmacokinetics were described successfully by a three-

291 Veliparib pharmacokinetics were dose proportional, with no effect

292 Pharmacokinetics were dose proportional, with no evidenc

293 of serum thromboxane generation and aspirin pharmacokinetics were measured in 40 patients with diabe

294 Plasma pharmacokinetics were modeled with a biexponential funct

295 TF2 and (68)Ga-IMP288 pharmacokinetics were monitored.

296 The tumor uptake, biodistribution, and pharmacokinetics were not significantly different from t

297 erall survival, leukaemia-free survival, and pharmacokinetics will be reported at the end of the phas

298 ition, this technique characterized cellular pharmacokinetics with heterogeneous delivery after 1 day

299 macology models that integrated cellular PTX pharmacokinetics with PTX pharmacodynamics successfully

300 ld potentially be developed to achieve novel pharmacokinetics, without consideration of that particul